SCHEMBL10036716

SCHEMBL10036716

Cc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 16/20 0.79
ADRB1 P08588 7/20 0.79
ADRB3 P13945 5/20 0.79
CYP3A4 P08684 5/20 0.79
MAPK1 P28482 5/20 0.79
CYP2D6 P10635 3/20 0.79
TSHR P16473 3/20 0.79
DRD2 P14416 2/20 0.79
CYP1A2 P05177 2/20 0.79
SLC6A4 P31645 2/20 0.79
ADRA1A P35348 2/20 0.79
SLC6A3 Q01959 2/20 0.79
PGR P06401 1/20 0.79
PTGS2 P35354 1/20 0.79
CYP2C19 P33261 1/20 0.79
DRD3 P35462 1/20 0.79
HIF1A Q16665 2/20 0.64
HSD17B10 Q99714 2/20 0.64
NFKB1 P19838 1/20 0.64
RAB9A P51151 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430362 0.92 ADRB2 (0.80) ADRB2ADRB1ADRB3CYP3A4MAPK1
SCHEMBL11819755 0.90 ADRB2 (0.65) ADRB2ADRB1ADRB3CYP3A4MAPK1
SCHEMBL11817913 0.90 ADRB2 (0.77) ADRB2ADRB1ADRB3CYP3A4MAPK1
Formoterol SCHEMBL15856256 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1
Arformoterol SCHEMBL6547706 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1
Arformoterol SCHEMBL117865 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1
Arformoterol SCHEMBL4247 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1
Arformoterol SCHEMBL458736 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1
Arformoterol SCHEMBL3679114 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1
Formoterol SCHEMBL6528975 0.88 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9730890-B2 Bronchodilating beta-agonist compositions and methods MYLAN PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-20150209311-A1 (R,R) FORMOTEROL IN COMBINATION WITH OTHER PHARMACOLOGICAL AGENTS SUNOVION PHARMACEUTICALS INC. (US) 2015-07-30 US disclosed
US-8623851-B2 Formoterol/steroid bronchodilating compositions and methods of use thereof MYLAN SPECIALTY L.P. (US) 2014-01-07 US disclosed
US-8623922-B2 Bronchodilating Beta-agonist compositions and methods DEY PHARMA, L.P. (US) 2014-01-07 US disclosed
US-20120309837-A1 Bronchodilating Beta-Agonist Compositions and Methods BANERJEE PARTHA S (US) 2012-12-06 US disclosed
US-8114912-B2 Bronchodilating β-agonist compositions and methods MYLAN PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
US-20110166202-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF DEY, L.P. (US) 2011-07-07 US disclosed
US-20100240761-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS DEY, L.P. (US) 2010-09-23 US disclosed
US-20100120734-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF DEY, L.P. (US) 2010-05-13 US disclosed
US-20100069342-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF DEY, L.P. (US) 2010-03-18 US disclosed
US-7465756-B2 Bronchodilating beta-agonist compositions and methods JPMORGAN CHASE BANK, N.A. (US) 2008-12-16 US disclosed
US-7462645-B2 Bronchodilating beta-agonist compositions and methods JPMORGAN CHASE BANK, N.A. (US) 2008-12-09 US disclosed
US-20080293788-A1 Methods and Compositions for the Treatment of Pulmonary Diseases SEPRACOR INC. 2008-11-27 US disclosed
US-20080125461-A1 (R,r)-Formoterol in Combination with Other Pharmacological Agents SEPRACOR INC. (US) 2008-05-29 US disclosed
US-7348362-B2 Bronchodilating β-agonist compositions and methods DEY, L.P. (US) 2008-03-25 US disclosed
US-20070166235-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS DEY, L.P. (US) 2007-07-19 US disclosed
US-20070166236-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS DEY, L.P. (US) 2007-07-19 US disclosed
US-20070166240-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS DEY, L.P. (US) 2007-07-19 US disclosed
US-20070160541-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS DEY, L.P. (US) 2007-07-12 US disclosed
US-3994974-A BRONCHODILATORS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166202-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF ADRB2, CYP11B2, ADRB3 ADRB2 1/4885ADRB1 4/4885ADRB3 3/4885
US-20070166236-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS ADRB2, ADRB3, ADRB1 ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885
US-20100240761-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS ADRB2, ADRB3, ADRB1 ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885
US-20120309837-A1 Bronchodilating Beta-Agonist Compositions and Methods ADRB2, ADRB3, ADRB1 ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885
US-20100120734-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF ADRB2, CYP11B2, ADRB3 ADRB2 1/4885ADRB1 4/4885ADRB3 3/4885
US-20070160541-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS ADRB2, ADRB3, ADRB1 ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885
US-20070166235-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS ADRB2, ADRB3, ADRB1 ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885
US-20080293788-A1 Methods and Compositions for the Treatment of Pulmonary Diseases KCNN3, KCNN2, KCNN1 ADRB2 164/4885ADRB1 178/4885ADRB3 163/4885
US-20100069342-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF ADRB2, CYP11B2, ADRB3 ADRB2 1/4885ADRB1 4/4885ADRB3 3/4885
US-20150209311-A1 (R,R) FORMOTEROL IN COMBINATION WITH OTHER PHARMACOLOGICAL AGENTS LTB4R, LTB4R2, TACR1 ADRB2 15/4885ADRB1 22/4885ADRB3 39/4885
US-20080125461-A1 (R,r)-Formoterol in Combination with Other Pharmacological Agents LTB4R, LTB4R2, CYSLTR1 ADRB2 14/4885ADRB1 22/4885ADRB3 37/4885
US-20070166240-A1 BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS ADRB2, ADRB3, ADRB1 ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.